Myelodysplastic Syndromes (MDS)

Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes

Background: The lower-risk (low and intermediate-1 risk based on IPSS) myelodysplastic syndrome (MDS) has a negative impact on patients' health-related quality of life (HRQoL). Patient Reported Outcomes (PROs) instruments, which are used to collect patients' HRQoL data, should have established content validity in the target population to ensure that the instrument is comprehensive and comprehensible.

TP53 Mutation Status Possesses Prognostic Implications in MDS

Original Publication Date
Article Source
External Web Content
Patients with myelodysplastic syndromes (MDS) who have biallelic TP53 have worse outcomes, such as treatment-resistant disease, rapid disease progression, and low overall survival, versus those with monoallelic mutations, according to results from a study published in Nature…

Robert Collins, MD

Institution
Harold C. Simmons Comprehensive Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
A recognized leader in the field of adoptive immunotherapy, Dr. Collins specializes in blood and marrow transplantation and hematologic malignancies such as leukemia, lymphoma, myeloma, Hodgkin’s disease, and myelodysplasia. Dr. Collins earned his medical degree from the University of Missouri-Kansas City School of Medicine. He completed an internal medicine residency at Baylor University Medical Center in Dallas, as well as a fellowship in hematology and oncology at the University of California at Los Angeles. Board-certified in internal medicine and medical oncology, Dr. Collins has 25 years

Vijaya Bhatt, MD

Institution
University of Nebraska Medical Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Vijaya Raj Bhatt graduated from Institute of Medicine, Tribhuvan University in Nepal in 2009 with a degree of Bachelor of Medicine and Bachelor of Surgery (MBBS). He then went on to do a three-year residency in internal medicine in Staten Island University Hospital in Staten Island, New York. During his residency, he was awarded the resident of the year for three consecutive years. After completing his residency, he joined the University of Nebraska Medical Center in Nebraska and completed his fellowship in hematology-oncology. He has authored or co-authored 127 articles, 18 book chapters

Pinkal Desai, MD, MPH

Institution
New York Presbyterian Hospital/Weill Cornell Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
After obtaining her MBBS at Byramjeejeebhoy Medical College in India in 2005, Dr. Desai obtained an MPH at the University of Alabama at Birmingham School of Public Health. Following her residency at Wayne State University, Detroit Medical Center, she underwent fellowship training in Hematology-Medical Oncology at Providence Hospital Medical Center, serving as Chief Fellow from 2012-2013. Dr. Desai was recruited to serve in our Leukemia Program to develop a clinical practice devoted to leukemia, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). She will be developing

Carlos E. Vigil, MD

Institution
University of Iowa Clinic and Hospitals
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
About
Carlos E. Vigil, MD, is a hematologist who holds an appointment as Clinical Assistant Professor at the University of Iowa Hospitals and Clinics. Dr. Vigil achieved his medical degree at the Universidad Peruana Cayetano Heredia in Lima, Peru, completed his residency in Internal Medicine at Henry Ford Hospital in Detroit and completed three fellowships at H. Lee Moffitt Cancer Center (Hematology-Oncology), Leukemia (M.D. Anderson Cancer Center) and Hematopoetic Stem Cell Transplant (Vanderbilt University Medical Center). Dr. Vigil is an active researcher focusing on MDS, AML and other leukemias.
Subscribe to Myelodysplastic Syndromes (MDS)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.